AR029198A1 - Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos - Google Patents

Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos

Info

Publication number
AR029198A1
AR029198A1 ARP000106396A ARP000106396A AR029198A1 AR 029198 A1 AR029198 A1 AR 029198A1 AR P000106396 A ARP000106396 A AR P000106396A AR P000106396 A ARP000106396 A AR P000106396A AR 029198 A1 AR029198 A1 AR 029198A1
Authority
AR
Argentina
Prior art keywords
derivatives
adenosine
manufacture
pharmaceutical compositions
heterociclic
Prior art date
Application number
ARP000106396A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR029198A1 publication Critical patent/AR029198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados de adenosina 8 modificados heterocíclicos N6 de acuerdo a la formula general (1), en donde Ra a R6 y Xa tienen los significados dados en la memoria descriptiva, composiciones farmacéuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento que son selectivos agonistas parciales o totales del receptor A1 de adenosina, y como tales, son utiles para modificar la actividad cardíaca, modificar la funcion de adipocitos, tratar desordenes del sistema nervioso central y tratar desordenes diabéticos y obesidad en mamíferos, y especialmente en humanos.
ARP000106396A 1999-12-03 2000-12-01 Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos AR029198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,485 US6294522B1 (en) 1999-12-03 1999-12-03 N6 heterocyclic 8-modified adenosine derivatives

Publications (1)

Publication Number Publication Date
AR029198A1 true AR029198A1 (es) 2003-06-18

Family

ID=23804799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106396A AR029198A1 (es) 1999-12-03 2000-12-01 Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos

Country Status (20)

Country Link
US (2) US6294522B1 (es)
EP (1) EP1237898B1 (es)
JP (1) JP4021196B2 (es)
KR (1) KR100484987B1 (es)
CN (1) CN1195772C (es)
AR (1) AR029198A1 (es)
AT (1) ATE292140T1 (es)
AU (1) AU771242B2 (es)
CA (1) CA2394861C (es)
DE (1) DE60019164T2 (es)
ES (1) ES2236044T3 (es)
HK (1) HK1051695B (es)
IL (2) IL149651A0 (es)
MX (1) MXPA02005318A (es)
NO (1) NO323138B1 (es)
NZ (1) NZ518736A (es)
TR (1) TR200201470T2 (es)
TW (1) TWI268923B (es)
WO (1) WO2001042265A2 (es)
ZA (1) ZA200204379B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US20050118605A9 (en) * 1996-06-06 2005-06-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20040171032A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040161844A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040161777A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6576620B2 (en) * 1999-12-03 2003-06-10 Cv Therapeutics, Inc. Method of identifying partial adenosine A1 receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
JP2005527502A (ja) * 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1560840B1 (en) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291753B2 (en) * 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
CA2544678C (en) * 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CA2580236A1 (en) * 2004-09-17 2006-03-23 Kissei Pharmaceutical Co., Ltd. Purinenucleoside derivative modified in 8-position and medical use thereof
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
SI2444079T1 (sl) 2005-05-17 2017-05-31 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje očesnih motenj
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
EP2209371B1 (en) 2007-10-19 2017-01-04 SARcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
ES2763703T3 (es) * 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2265124A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
CN102164591A (zh) * 2008-09-29 2011-08-24 吉利德科学股份有限公司 速率控制剂和A-2-α受体拮抗剂的组合用于多检测器计算机化断层显像方法
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
CZ308881B6 (cs) 2014-12-09 2021-08-04 Univerzita Palackého v Olomouci 6-aryl-9-glykosylpuriny a jejich použití
GB201820685D0 (en) * 2018-12-19 2019-01-30 NuCana plc Synthesis of 8-chloroadenosine derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2881164A (en) * 1955-07-18 1959-04-07 American Cyanamid Co Ribofuranosyl derivatives of 6-aralkylamino and 6-heterocyclicalkylaminopurines
US3150124A (en) * 1962-03-16 1964-09-22 Svarnas George Synthesis of kinetin glycosides
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
US4616003A (en) * 1984-10-26 1986-10-07 Warner-Lambert Company N6 -dihydroxypropyladenosines
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
US5236902A (en) * 1990-11-26 1993-08-17 The Governors Of The University Of Alberta Method and probes for detecting nucleoside transporter and method for producing the probes
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
WO1993021929A1 (en) * 1992-05-01 1993-11-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phosphorothioate derivatives of cyclic amp analogues
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
JPH07324035A (ja) * 1994-05-30 1995-12-12 L T T Kenkyusho:Kk 滑膜細胞増殖抑制剤及び慢性関節リウマチ治療剤
CA2191245A1 (en) 1994-06-09 1995-12-14 Kazuo Yamazaki 4-quinolinone derivative or salt thereof
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20020045595A1 (en) 2002-04-18
WO2001042265A2 (en) 2001-06-14
AU4510101A (en) 2001-06-18
NO20022573D0 (no) 2002-05-30
KR20030032906A (ko) 2003-04-26
DE60019164T2 (de) 2006-02-02
ATE292140T1 (de) 2005-04-15
EP1237898B1 (en) 2005-03-30
AU771242B2 (en) 2004-03-18
IL149651A0 (en) 2002-11-10
WO2001042265A3 (en) 2002-01-03
JP2003516413A (ja) 2003-05-13
ZA200204379B (en) 2003-06-25
EP1237898A2 (en) 2002-09-11
JP4021196B2 (ja) 2007-12-12
TR200201470T2 (tr) 2002-12-23
CA2394861A1 (en) 2001-06-14
IL149651A (en) 2006-08-20
CN1195772C (zh) 2005-04-06
CN1402732A (zh) 2003-03-12
NO20022573L (no) 2002-05-30
HK1051695B (zh) 2005-06-03
TWI268923B (en) 2006-12-21
DE60019164D1 (de) 2005-05-04
ES2236044T3 (es) 2005-07-16
MXPA02005318A (es) 2002-12-11
NO323138B1 (no) 2007-01-08
CA2394861C (en) 2007-01-30
US6294522B1 (en) 2001-09-25
HK1051695A1 (en) 2003-08-15
NZ518736A (en) 2004-02-27
KR100484987B1 (ko) 2005-04-22

Similar Documents

Publication Publication Date Title
AR029198A1 (es) Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
AR029199A1 (es) Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
BR0207952A (pt) Moduladores da atividade de receptores de quimiocina
UY30783A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
BRPI0511477A (pt) compostos e composições como moduladores de ppar
NO20060871L (no) Azepinderivater som farmasoytiske midler
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
UY27939A1 (es) Compuestos
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
UY29300A1 (es) Compuestos quimicos
NO20043411L (no) Substituerte quinazolin-4-ylamin analoger
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
AR021893A1 (es) Compuesto de 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanona sustituida , su uso para la manufactura de un medicamento en el tratamiento de algunos trastornos del sistema nervioso central y periférico y composiciones farmacéuticas que las contienen
BRPI0510024A (pt) compostos e composições como modulares de ppar
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1

Legal Events

Date Code Title Description
FG Grant, registration